Wechter W J
Department of Medicine, School of Medicine, Loma Linda University, California 92350.
J Clin Pharmacol. 1994 Nov;34(11):1036-42. doi: 10.1002/j.1552-4604.1994.tb01977.x.
This review summarizes and comments on the current understanding of both the biochemical and clinical implications of the epimerization of R-aryl propionic (APA) class (1) nonsteroidal anti-inflammatory agents (NSAIDs) to S-enantiomers in humans. This article focuses principally on rac-ibuprofen and its enantiomers. In the United States, five commercialized NSAIDs are APAs. Only two of them, rac-ibuprofen and rac-fenoprofen, are subject to significant epimerization in humans. The remaining three, rac-flurbiprofen, rac-ketoprofen, and S-naproxen, are not of interest in this context.
本综述总结并评论了目前对R-芳基丙酸(APA)类(1)非甾体抗炎药(NSAIDs)在人体内差向异构化为S-对映体的生化及临床意义的理解。本文主要聚焦于消旋布洛芬及其对映体。在美国,有五种商业化的NSAIDs属于APAs。其中只有两种,即消旋布洛芬和消旋非诺洛芬,在人体内会发生显著的差向异构化。其余三种,即消旋氟比洛芬、消旋酮洛芬和S-萘普生,不在本文讨论范围内。